

National shared care protocol adapted for local use:

Management of neuroinflammatory diseases in adults with the steroid sparing agent azathioprine (non-transplant indications)

The content of this shared care protocol was correct as of May 2024. Please ensure that [summaries of product characteristics](#) (SPCs), [British national formulary](#) (BNF) or the [Medicines and Healthcare products Regulatory Agency](#) (MHRA) or [NICE](#) websites are reviewed for up-to-date information on any medicine.

Specialist responsibilities

- Assess the patient and provide diagnosis; ensure that this diagnosis is within the scope of this shared care protocol ([section 2](#)) and communicated to primary care.
- Use a shared decision making approach; discuss the benefits and risks of the treatment with the patient and provide the appropriate counselling (see [section 11](#)) to enable the patient to reach an informed decision. Obtain and document patient consent. Provide an appropriate patient information leaflet.
- Assess for contraindications and cautions (see [section 4](#)) and interactions (see [section 7](#)).
- Conduct required baseline investigations and initial monitoring (see [section 8](#)).
- Initiate and optimise treatment as outlined in [section 5](#).
- Prescribe sufficient medication (usually 42 days) to enable transfer to primary care, including where there are unforeseen delays to transfer of care. Further prescriptions will be issued if, for unseen reasons, arrangements for shared care are not in place at the end of 42 days. Patients should not be put in a position where they are unsure where to obtain supplies of their medication. The specialist team will be responsible for monitoring and prescribing the medicine during this initial period.
- Transfer to primary care is normally after the patient has been treated for 3 months and with satisfactory investigation results for at least 4 weeks.
- If shared care is considered appropriate, and once treatment is optimised, write to the patient's GP practice and request shared care, detailing the diagnosis, the current and ongoing dose, baseline and most recent test results, confirm the monitoring schedule and when the next monitoring is required. Include the specialist service contact information ([section 13](#)).
- The specialist should also provide the details of the treatment to be undertaken by the GP. Including the reasons for the choice of treatment, medicine combination, frequency of treatment, and the next review date by the specialist.

- Conduct the required monitoring in [section 8](#) and communicate the results in writing to primary care within 14 days, where possible. After each review, provide primary care with a written summary within 14 days, advising whether treatment should be continued, confirming the ongoing dose, and whether the ongoing monitoring outlined in [section 9](#) remains appropriate.
- Provide the patient with a patient information sheet and details of their treatment, including any dosage changes made, follow-up appointments, monitoring requirements, and specialist team contact details. Highlight the importance of monitoring the patient and explain the potential withdrawal of treatment if monitoring appointments are not attended.
- Review patients annually.
- Give advice to primary care on continuing treatment if a woman becomes or wishes to become pregnant or breastfeed.
- Provide advice to primary care on the management of adverse effects if required.
- Contact details for primary care prescribers during working and non-working hours will be made available.
- Details for fast-track referral will be supplied.

Primary care responsibilities

- If shared care is not accepted, inform the specialist of the decision in writing within 14 days with reasons as to why shared care cannot be entered into.
- If shared care is accepted, ensure knowledge and understanding of the therapeutic issues relating to the patient's clinical condition. Undergo any additional training necessary to carry out the prescribing and monitoring requirements.
- Agreeing that in his / her opinion the patient should receive shared care for the diagnosed condition unless good reasons exist for the management to remain within secondary care.
- If accepted, prescribe ongoing treatment as detailed in the specialist's request and as per [section 5](#) taking into account any potential drug interactions in [section 7](#).
- Adjust the dose of azathioprine prescribed as advised by the specialist and communicate any changes made to the patient.
- Conduct the required monitoring as outlined in [section 9](#). Communicate any abnormal results to the specialist.
- Ensure the patient is given the appropriate follow-up and monitoring appointments. If a patient fails to attend, contact the patient in a timely manner to arrange alternative appointments. It is the GP's responsibility to decide whether to continue treatment in a patient who does not attend follow-up and monitoring appointments. If the patient regularly fails to attend the monitoring appointment, the GP may withhold the prescription and inform the consultant responsible for the patient's care.
- Assess for possible interactions with azathioprine when starting new medicines (see [section 7](#)).
- Manage any adverse effects as detailed in [section 10](#) and discuss them with the specialist team when required. Refer the patient back to the specialist team if further investigation is required.
- Stop azathioprine and discuss urgently with the specialist if bone marrow suppression is suspected.

- Discuss other adverse effects with the specialist team as clinically appropriate (see [section 10](#)).
- Contact the specialist team for advice if the patient becomes or plans to become pregnant.
- Stop treatment as advised by the specialist.
- Offer patients vaccination in line with the current Joint Committee on Vaccination and Immunisation advice. ([Immunisation against infectious disease](#)).

Patient and/or carer responsibilities

- Take azathioprine as prescribed and do not stop taking it without speaking to their primary care prescriber or specialist.
- Tell anyone who prescribes them a medicine that they are taking azathioprine.
- Attend regularly for monitoring and review appointments with primary care and specialist. If unable to attend, inform the relevant practitioner as soon as possible and arrange an alternative appointment. Be aware that medicines may be stopped if they do not attend appointments.
- Report adverse effects to their primary care prescriber. Seek immediate medical attention if they develop any symptoms as detailed in [section 11](#).
- Report the use of any over the counter (OTC) medications to their prescriber and be aware they should discuss the use of azathioprine with their pharmacist before purchasing any OTC medicines.
- Store the medication securely away from children.
- Read the information supplied by the GP, specialist, and pharmacist, and contact the relevant practitioner if they do not understand any of the information given. Inform the specialist or primary care prescriber as soon as possible if they become pregnant or wish to become pregnant.

1. Background

[Back to top](#)

Azathioprine is of proven benefit as a disease modifying agent in the treatment of neuroinflammatory conditions which respond to steroids. Failure to control neurological symptoms with a 'safe' dose of corticosteroids is the main indication for starting immunosuppression. Clinical improvement may take up to three months. Steroids and other symptomatic treatments (such as pyridostigmine in myasthenia gravis) may need to be continued. Patient reported adverse effects usually occur early in therapy, but please see adverse effects management as detailed in [section 10](#).

Azathioprine is not licensed for all the conditions it is used to treat, as noted below. However, its use for the indications below are established and supported by various sources and bodies including the BNF, NICE, Association of British Neurologists (ABN).

2. Indications

[Back to top](#)

The autoimmune neurological conditions covered by this agreement can be broadly split into four major categories:

- 1) Neuromuscular junction disorders – Most commonly myasthenia gravis, although can be paraneoplastic (such as Lambert-Eaton myasthenic syndrome), this antibody mediated condition can cause ptosis, oculomotor, bulbar, diaphragmatic and limb weakness. The clinical phenotype characterised by fatiguable weakness with supportive tests such as the presence of antibodies and electromyography is required for diagnosis. The mainstay of treatment is immunosuppression with adjunctive therapy with a cholinesterase inhibitor for symptomatic relief where applicable. Patients with symptoms in excess of ocular involvement require immunosuppression.
- 2) Inflammatory neuropathies – Most commonly chronic inflammatory demyelinating polyneuropathy (CIDP), these immune mediated neuropathies usually cause limb weakness and sensory disturbance, although can also cause cranial nerve and autonomic neuropathies. Clinical phenotype, cerebrospinal fluid analysis and neurophysiological tests confirm the diagnosis. Immunosuppression is the mainstay of treatment, with steroids and then steroid sparing agents first line. If these are unsuccessful, intravenous immunoglobulin and more aggressive therapies can be considered.
- 3) A subset of central nervous system inflammatory diseases, including neuromyelitis optica spectrum disorder (NMOSD), are steroid responsive and require long term therapy. Most are diagnosed on clinical phenotype, characteristic MRI features, serum antibodies and cerebrospinal fluid analysis. Immunosuppression is the mainstay of treatment, with steroids and then steroid sparing agents first line. If these are unsuccessful, intravenous immunoglobulin and more aggressive therapies can be considered. Other examples include CNS inflammation with anti-MOG antibodies and neurosarcoidosis.
- 4) Autoimmune encephalitis is typically characterised by neuropsychiatric symptoms, fever, movement disorders, autonomic dysfunction and seizures. Diagnosis is made on the clinical syndrome, serum antibodies, MRI findings and cerebrospinal fluid analysis. Treatments require expert guidance in the choice of immunosuppression as the mainstay of treatment, with steroids and then steroid sparing agents typically used as first line. If these are unsuccessful, intravenous immunoglobulin and more aggressive therapies can be considered.

These indications are off label. The initiating specialist must specify the indication for each patient when initiating shared care and clearly state when the use is off label.

This shared care protocol applies to adults aged 18 and over. It does not include use of azathioprine for transplant or oncology indications.

3. Locally agreed off-label use

[Back to top](#)

Neuromuscular diseases (such as Myasthenia Gravis, Lambert-Eaton Syndrome), inflammatory neuropathies (chronic inflammatory demyelinating polyneuropathy), inflammatory CNS conditions (such as Neuromyelitis optica), and autoimmune encephalitides (including antibody associated and paraneoplastic) - outside of license (supported by national guidance).

4. Contraindications and cautions

[Back to top](#)

This information does not replace the Summary of Product Characteristics (SPC) and should be read in conjunction with it. Please see [BNF](#) & [SPC](#) for comprehensive information.

Contraindications:

- Known hypersensitivity to the active substance or any excipients. Hypersensitivity to 6-mercaptopurine (6-MP) should alert the prescriber to probable hypersensitivity to azathioprine.
- Absent or very low thiopurine methyltransferase (TPMT) activity – risk of life-threatening pancytopenia.
- There is a debate as to whether taking azathioprine is a contraindication to using intrauterine contraceptive devices. This is based on a few case reports. There is probably no good reason to avoid intrauterine contraceptive devices, but specialist advice should be sought.

Cautions:

- Live vaccines (e.g., oral polio, oral typhoid, MMR, BCG, yellow fever): should be avoided in patients taking azathioprine at a dose greater than 3 mg/kg/day. Please refer to the [Green Book Chapter 6](#) for current advice regarding the use of live vaccines in patients taking immune modulators. Contact the specialist if further guidance is required. N.B. Routine influenza and pneumococcal vaccinations are highly recommended.
- Patients with active/history of pancreatitis.
- Concomitant prescribing of allopurinol: see [section 7](#).
- Patients receiving azathioprine are at an increased risk of developing lymphoproliferative disorders and other malignancies, notably skin cancers, sarcomas, and uterine cervical cancer in situ. Exposure to sunlight and UV light should be limited and patients should wear protective clothing and use a sunscreen with a high protection factor to minimise the risk of skin cancer and photosensitivity.
- Patients with low thiopurine methyltransferase (TPMT) activity are at increased risk of myelosuppression. Substantial dose reduction is generally required or increased monitoring. Specialist will determine action required in such a situation.
- Severe infection.
- Localised or systemic infection including hepatitis B or C and history of tuberculosis.
- Severely impaired hepatic or bone marrow function.
- Pregnancy and breastfeeding (see [section 12](#)).
- Patients who have no history of exposure to varicella zoster virus (VZV), i.e., chickenpox or herpes zoster (shingles), should avoid contact with individuals with chickenpox or herpes zoster. Varicella–zoster immunoglobulin (VZIG) is recommended for individuals who are at increased risk of severe varicella (including patients taking immunosuppressant medicines, (e.g., azathioprine, ciclosporin, methotrexate, leflunomide) who have no antibodies to varicella–zoster virus, and who have significant exposure to chickenpox or herpes zoster. If the patient is infected with VZV, appropriate measures should be taken, which may include antiviral therapy and supportive care.

Treatment may need to be monitored more frequently in the following:

- Elderly patients

- Impaired renal function. Dose reduction may be required in moderate or severe renal impairment. Please discuss with the neurology specialist team.
- Mild/moderately impaired hepatic function
- Mild/moderately impaired bone marrow function

5. Initiation and ongoing dose regimen

[Back to top](#)

- Transfer of monitoring and prescribing to primary care is normally after at least 12 weeks, and when the patient dose has been optimised and with satisfactory investigation results for at least 4 weeks.
- The duration of treatment & frequency of review will be determined by the specialist, based on clinical response and tolerability.
- All dose or formulation adjustments will be the responsibility of the initiating specialist unless directions have been discussed and agreed with the primary care clinician.
- Termination of treatment will be the responsibility of the specialist.

Initial stabilisation:

There is a wide dose range depending on the indication. The selected dose will be tailored to the individual patient and decided by the specialist.

Azathioprine is given orally once or twice a day. The usual starting dose is from 0.5 to 3 mg/kg body weight/day, increased over a period of one month.

The initial stabilisation period must be prescribed by the initiating specialist.

Transfer of monitoring and prescribing to primary care is usually after 3 months. The duration of treatment will be determined by the specialist based on clinical response and tolerability.

Maintenance dose (following initial stabilisation):

Azathioprine is given orally once or twice a day. The usual maintenance dose is in the range of 100mg-200mg per day.

When therapeutic response is evident, consideration should be given to reducing the maintenance dosage to the lowest level compatible with the maintenance of that response. If no improvement occurs in the patient's condition within 3 months, consideration should be given to withdrawing azathioprine.

Some patients may respond to lower doses. Please note patients may be initiated on more than one DMARD.

The initial maintenance dose must be prescribed by the initiating specialist.

Conditions requiring dose adjustment:

Lower doses may be required if there is significant renal or hepatic impairment, in elderly patients, and in patients with mild/moderately impaired bone marrow function, TPMT deficiency or NUDT15 mutation ([see SPC](#)).

Thiopurine methyltransferase (TMPT) should be measured in view of the association between TMPT deficiency and myelosuppression with azathioprine. TMPT deficiency is not a contraindication to using azathioprine but may reduce the dose required. Patients with very low TMPT activity should not take azathioprine.

Duration of treatment

Azathioprine has a cumulative action, and a clinical improvement can take up to three months, with a full therapeutic effect taking up to 6-12 months. It is standard practice to continue azathioprine therapy if tolerated for at least two years.

Decisions regarding dosage modification and withdrawal shall only be taken after discussion with treating specialist.

6. Pharmaceutical aspects

[Back to top](#)

Route of administration:	Oral
Formulation:	Azathioprine 25mg and 50mg tablets. Prescribe generically.
Administration details:	<p>The tablets should be swallowed whole and not split / crushed.</p> <p>Can be taken either with or without food, but patients should standardise which method is chosen. Tablets should be taken at least 1 hour before or 2 hours after milk or dairy products.</p> <p>Taking with or after food may relieve nausea, however the oral absorption of azathioprine may be reduced. Consideration should be given to monitoring therapeutic efficacy more closely if patient is taking azathioprine consistently with food.</p>
Other important information:	<p>Providing the film coating of azathioprine tablets remains intact, there is no risk or additional precautions required when handling tablets.</p> <p>Azathioprine is cytotoxic. It is recommended that they are handled following local recommendations for the handling and disposal of cytotoxic agents.</p>

7. Significant medicine interactions

[Back to top](#)

The following list is not exhaustive. Please see [BNF](#) or [SPC](#) for comprehensive information and recommended management.

The following drugs must not be prescribed without consultation with the specialist:

- **Allopurinol** has the potential to cause thiopurine toxicity and should be avoided, except with specialist input.
- **Febuxostat** has the potential to cause thiopurine toxicity; avoid in combination with azathioprine.
- **Live vaccines** (e.g., oral polio, oral typhoid, MMR, BCG, yellow fever) can be given to patients on stable long term low dose corticosteroid therapy (defined as ≤ 20 mg prednisolone per day for >14 days) alone or in combination with low dose non-biological oral immune modulating drugs (e.g. azathioprine up to 3mg/kg/day). Clinician discretion is advised. Please refer to the [Green Book Chapter 6](#) for current advice, and advice for patients taking higher doses.
- **Warfarin** – thiopurines may reduce anticoagulant effects of warfarin. Monitor closely and increase the dose of warfarin if necessary.
- **Phenytoin, sodium valproate, carbamazepine** absorption may be reduced by azathioprine.
- **Co-trimoxazole / trimethoprim** possible increased risk of haematological toxicity, however evidence is conflicting, and this combination is often used in practice.
- **Clozapine** - avoid due to increased risk of agranulocytosis.
- **Ribavirin** - increased risk of haematological toxicity when azathioprine given concurrently, and this combination should be avoided.
- **Aminosalicylates** (sulfasalazine, mesalazine or olsalazine) - increased risk of haematological toxicity with concomitant thiopurine due to TPMT inhibition. Dose adjustment of azathioprine and additional monitoring of FBC may be required.

The following drugs may be prescribed with caution:

- **ACE inhibitors** - increase the risk of anaemia and or leukopenia.
- **Cimetidine and indomethacin** - concomitant administration of thiopurines may increase the risk of myelosuppression.

8. Baseline investigations, initial monitoring and ongoing monitoring to be undertaken by specialist

[Back to top](#)

Monitoring at baseline and during initiation is the responsibility of the specialist; only once the patient is optimised on the chosen medication with no anticipated further changes expected in the immediate future will prescribing and monitoring be transferred to primary care.

Baseline investigations:

- Height and weight
- Blood pressure
- Full blood count (FBC)
- Urea and electrolytes (U&Es) & creatinine clearance (CrCl)
- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), and albumin
- Baseline thiopurine methyl transferase (TPMT) status
- Screening for viral infections as per local policy, e.g., HIV, hepatitis B and C, varicella zoster, Epstein Barr virus, cytomegalovirus
- Screening for lung disease, including tuberculosis, should be undertaken at clinician discretion on a case-by-case basis.
- Confirm cervical screening is up to date.

Provide or request appropriate vaccination prior to treatment initiation, according to local arrangements (e.g., pneumococcal, shingles, influenza, COVID-19)

Initial monitoring and at dose change:

To be repeated every 2 weeks until the dose has been stable for 6 weeks, then monthly for 3 months, and then 3 monthly thereafter.

- FBC
- U&Es, including creatinine and CrCl
- LFTs, including AST and/or ALT, and albumin.

Following a dose increase repeat every 2 weeks until the dose has been stable for 6 weeks, then revert to previous schedule. More frequent monitoring is appropriate in patients at higher risk of toxicity.

Ongoing monitoring:

The specialist will retain the responsibility for monitoring the patient's ongoing response to treatment and advise if a dose change or treatment cessation is appropriate. **This should usually be undertaken annually.**

After each review, advise primary care whether treatment should be continued, confirm the ongoing dose, and whether the ongoing monitoring outlined in [section 9](#) remains appropriate.

In cases where shared care arrangements are not in place, or where problems have arisen within the agreement and patient care may be affected, the responsibility for the patient's management including prescribing reverts back to the Specialist.

9. Ongoing monitoring requirements to be undertaken by primary care

[Back to top](#)

See [section 10](#) for further guidance on management of adverse effects/responding to monitoring results.

Monitoring and actions	Frequency
<ul style="list-style-type: none"> • FBC • U&Es including creatinine and CrCl • ALT and/or AST, and albumin 	<p>Monthly for three months, unless already completed in secondary care. Thereafter at least every 12 weeks, and more frequently in patients at higher risk of toxicity, as advised by the specialist team.</p> <p>The exact frequency of monitoring to be communicated by the specialist in all cases.</p>
<p>Patients aged from 50 years who are severely immunosuppressed and have not received the shingles vaccine before will be eligible for the shingles vaccine (varicella zoster). This will be provided as two doses of the non-live vaccine. If patient is taking additional DMARDs, check advice for all drugs. Please refer to Green Book Chapter 6 and Chapter 28a (Shingles) for further details.</p> <p>Annual influenza (The Green Book, Chapter 19) vaccinations are highly recommended</p> <p>COVID-19 vaccination is safe and recommended (see The Green Book, Chapter 14a).</p> <p>Repeat pneumococcal vaccines are highly recommended. See Green Book Chapter 25 for advice.</p>	<ul style="list-style-type: none"> • Shingles vaccination: one-off course. • Influenza vaccination: annual. It is advisable to add the patient to the influenza vaccine list. • COVID-19 vaccination as per national schedule.
<p>(If relevant) If monitoring results are forwarded to the specialist team, please include clear clinical information on the reason for sending, to inform action to be taken by secondary care.</p>	

10. Adverse effects and other management

[Back to top](#)

Any serious adverse reactions should be reported to the MHRA via the Yellow Card scheme. Visit www.mhra.gov.uk/yellowcard

For a full list of side effects and information on incidence of ADRs, refer to the BNF or see relevant summaries of product characteristics.

IF YOU ARE IN ANY DOUBT ABOUT ANY POTENTIAL ADVERSE REACTION, PLEASE CONTACT THE RHEUMATOLOGY SPECIALIST TEAM.

Result	Action for primary care
<p>As well as responding to absolute values in laboratory tests, a rapid change or a consistent trend in any value should prompt caution and extra vigilance.</p> <p>Other benchmark values may be set by secondary care in specific clinical circumstances. This will be communicated by the specialist.</p>	
<p>Full blood count:</p> <ul style="list-style-type: none"> • White blood cells less than $3.5 \times 10^9/L$ • Lymphocytes less than $0.5 \times 10^9/L$ • Neutrophils less than $1.6 \times 10^9/L$ • Platelets less than $140 \times 10^9/L$ • Eosinophilia greater than $0.5 \times 10^9/L$ 	<p>Discuss urgently with specialist team and consider interruption.</p> <p>NB - Isolated lymphopenia or eosinophilia is often a feature of the underlying autoimmune indication and is rarely an indication to discontinue azathioprine.</p>
<p>Mean cell volume >105 fl</p> <p>NB: Reversible, dose-related increases in mean corpuscular volume are a known effect of thiopurines.</p>	<p>Consider interruption in treatment if there is a significant increase from baseline.</p> <p>Check serum folate, B12, alcohol history and TSH and treat any underlying abnormality. If results of these additional investigations are normal discuss with specialist team urgently.</p>
<p>Signs or symptoms of bone marrow suppression, e.g., unexplained bleeding or bruising with or without sore throat, mouth ulcers, severe sore throat, fever</p>	<p>Consider interruption in treatment. Check FBC immediately and discuss with the specialist team. See haematological monitoring above.</p>
<p>Infections:</p> <p>Infection requiring antibiotics</p>	<p>Temporarily withhold thiopurine until the patient has recovered. Consider additional investigations (e.g., FBC), if clinically appropriate.</p>

<p>Liver function tests:</p> <ul style="list-style-type: none"> • ALT or AST >100 units/L, or any sudden increases (e.g., double of baseline), OR • Unexplained fall in serum albumin <30g/L (in the absence of active disease) • Jaundice 	<p>Withhold and discuss with specialist team.</p> <p>When used for hepatology indications, continue treatment, and discuss with specialist urgently.</p> <p>Check any other reason for risk of hepatic dysfunction such as alcohol history and drug interactions, including OTC or complementary medication.</p>
<p>Renal function:</p> <p>Creatinine rise >30% over 12 months, or calculated GFR reduces to <60ml/min</p>	<p>Withhold and discuss with specialist team</p>
<p>Gastrointestinal disorders:</p> <p>Nausea, vomiting or diarrhoea.</p>	<p>Review for reversible causes. Advise patient to take with food. In some individual, nausea will normally resolve after a few days. If troublesome prescribe antiemetic. If no improvement, contact specialist team.</p>
<p>Suspected pancreatitis</p>	<p>Withhold and discuss with specialist team.</p>
<p>Worsening neurological symptoms including weakness, difficulty swallowing and breathlessness</p>	<p>Myasthenia gravis and other neuro-inflammatory conditions may relapse on corticosteroid withdrawal. This may be a consequence of a slow response to azathioprine or using too low a dose. Discuss urgently with neurology specialist team for advice</p>
<p>Severe general malaise and flu- like symptoms or rash</p>	<p>This may be an early hypersensitivity reaction. Withhold and discuss with neurology specialist team.</p>

11. Advice to patients and carers

[Back to top](#)

The specialist will counsel the patient with regard to the benefits and risks of treatment and will provide the patient with any relevant information and advice, including patient information leaflets on individual medicines.

The patient should be advised to report any of the following signs or symptoms to their primary care prescriber without delay:

- Signs or symptoms indicating haematological toxicity, e.g., sore throat, infection, unexplained or abnormal bruising or bleeding.
- Signs or symptoms of pancreatitis, e.g., abdominal pain, nausea, or vomiting.
- Signs of symptoms of hepatic toxicity, e.g., jaundice (yellowing of the skin or whites of the eyes)

The patient should be advised to:

- That azathioprine should not be taken with dairy products (at least 1 hour before or 2 hours after milk or dairy products).
- During a serious infection azathioprine should be temporarily discontinued until the patient has recovered from the infection.
- That vaccination in line with current national advice (e.g., for COVID-19, influenza) is safe and recommended.
- Tell anyone who prescribes them a medicine that they are taking azathioprine. Always ask a pharmacist before purchasing any medicines over the counter, including herbal remedies, and ask if they are safe.
- To inform their specialist or primary care prescriber promptly if pregnancy occurs or is planned.
- All women aged 25-64 years old should be encouraged to participate in national cervical cancer screening programmes. There is no need to attend more frequently than recommended.
- Patients have a small increased risk of skin cancers so should be advised to wear high factor sunscreen and to wear a hat and protective clothing when in strong sunshine. Sun beds should be avoided. Patients should be advised to carry out regular self-examination of the skin and report if there are any new lesions and/or changes to skin.
- Patients taking azathioprine at a dose of 3 mg/kg or more (this is higher than the dose usually used in neurology practice) should be advised to avoid contact with people with chicken pox or shingles and report any such contact urgently to their primary care prescriber. If the patient is exposed, contact the specialist for advice. For detailed advice on risk assessment and post exposure prophylaxis following exposure to chicken pox and shingles, see:
- The [Green Book \(Chapter 34\)](#)
- UKSHA guidance: [Guidelines on post exposure prophylaxis \(PEP\) for varicella/shingles April 2022](#)

Patient information:

- General information: <https://www.nhs.uk/medicines/azathioprine/>
- General information: <https://patient.info/medicine/azathioprine-azapress-imuran>
- Patient information leaflets are also available from <https://www.medicines.org.uk/emc/search?q=azathioprine>
- [Local patient information leaflet](#)

12. Pregnancy, paternal exposure, and breast feeding

[Back to top](#)

It is the responsibility of the specialist to provide advice on the need for contraception to male and female patients on initiation and at each review, but the ongoing responsibility for providing this advice rests with both the primary care prescriber and the specialist.

All patients should be informed of the risks and benefits of taking this medicine during pregnancy and breastfeeding. The specialist team should be contacted if a patient becomes pregnant or is planning to become pregnant or breastfeed.

Pregnancy:

Pregnancy: Azathioprine has been safely used in pregnancy and is considered low risk while other immunosuppressive agents carry a clearer risk to the fetus. However, women wishing to become pregnant or men who wish to start a family should be discussed with the specialist team.

Information for patients and carers: [Azathioprine \(medicinesinpregnancy.org\)](https://www.medicinesinpregnancy.org/Azathioprine)

Breastfeeding:

Azathioprine is compatible with breastfeeding, although the active metabolite mercaptopurine is present in breast milk. A risk versus benefit assessment is advised. If used during breastfeeding, monitor for signs of infection or immunosuppression. If high doses of azathioprine are used, monitor infant blood counts.

Information for healthcare professionals:

- <https://www.sps.nhs.uk/medicines/azathioprine/>

Paternal exposure:

Azathioprine is compatible with paternal exposure. There is currently no evidence of adverse foetal effects relating to paternal use.

- Information for healthcare professionals: <https://www.medicinesinpregnancy.org/bumps/monographs/PATERNAL-USE-OF-AZATHIOPRINE-OR-MERCAPTOPYRINE/>

13. Specialist contact information

[Back to top](#)

Name: Named Neurology Consultant as per clinic letter

Role and specialty: Consultant Neurologist

Daytime telephone number: Nottingham University Hospitals (NUH)- 0115 924 9924 + request consultant's secretary

Sherwood Forest Hospitals (SFH) - Switchboard 01623 622515 + request consultant's secretary

Working Hours: 9 am - 5 pm

Out of hours contact details: Via on call Neurology SpR at NUH

Fast Track Referral as per above

14. Additional information

[Back to top](#)

Where patient care is transferred from one specialist service or GP practice to another, a new shared care agreement must be completed. Ensure that the specialist is informed in writing of any changes to the patient's GP or their contact details.

15. References

[Back to top](#)

- eBNF accessed via <https://bnf.nice.org.uk/> on 13/03/2024.
- Azathioprine 50mg tablets (Imuran®). Aspen. Date of revision of the text: May 2022. Accessed via <https://www.medicines.org.uk/emc/product/3823> on 13/03/2024.
- Association of British Neurologists. 2015. [Myasthenia gravis: management guidelines](#). Accessed 15/02/2024
- Public Health England. [Immunisation against infectious disease: The Green Book](#). Accessed 01/10/2020.
- Specialist Pharmacy Service. Lactation Safety Information: azathioprine. Reviewed September 2020. Accessed via <https://www.sps.nhs.uk/medicines/> on 13/03/2024.
- UK Teratology Information Service. Toxbase monograph: Azathioprine or mercaptopurine in pregnancy. December 2019. Accessed via www.toxbase.org on 06/10/2021.
- UK Teratology Information Service. Toxbase monograph: Paternal use of azathioprine or mercaptopurine. December 2019. Accessed via www.toxbase.org on 06/10/2021.

16. Other relevant national guidance

[Back to top](#)

- Shared Care for Medicines Guidance – A Standard Approach (RMOC). Available from <https://www.sps.nhs.uk/articles/rmoc-shared-care-guidance/>
- NHSE guidance – Responsibility for prescribing between primary & secondary/tertiary care. Available from <https://www.england.nhs.uk/publication/responsibility-for-prescribing-between-primary-and-secondary-tertiary-care/>
- General Medical Council. Good practice in prescribing and managing medicines and devices. Shared care. Available from <https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-practice-in-prescribing-and-managing-medicines-and-devices/shared-care>
- NICE NG197: Shared decision making. Last updated June 2021. <https://www.nice.org.uk/guidance/ng197/>.

17. Local arrangements for referral

[Back to top](#)

Define the referral procedure from hospital to primary care prescriber & route of return should the patient's condition change.

- The request for shared care should be accompanied by individual patient information, outlining all relevant aspects of the patient's care and which includes direction to the information sheets at the [APC website](#).
- Prescribing and monitoring responsibility will only be transferred when it is agreed by the specialist and the patient's primary care prescriber that the patient is stabilised on their medication regimen without adverse effect and with benefits demonstrated.
- The specialist will request shared care with the GP in writing.
- If the GP doesn't agree to shared care, they should inform the specialist of their decision in writing within 14 days, outlining the reason for the decline. The agreement can be assumed if the GP does not provide a written decline.
- In cases where shared care arrangements are not in place or where problems have arisen within the agreement, and patient care may be affected, the responsibility for the patient's management, including prescribing, reverts back to the specialist.
- Should the patient's condition change, the GP should contact the relevant specialist using the details provided with the shared care request letter.

Azathioprine SCP			
Version	Author(s)	Date	Changes
V1.0	Vimbayi Mushayi, Medicine Optimisation and Interface Pharmacist	May 2024	Adopted from the National template published by NHS England in July 2022. The information is cross-referenced between the national template and the local shared care guidelines. Additional information included to reflect the locally agreed shared care protocol. Consultations: <ul style="list-style-type: none">▪ Dr Christopher Allen Neurology Consultant NUH▪ Dr Bruno Gran Neurology Consultant NUH▪ Alisha Brown Neurology Specialist Pharmacist NUH